BioSpace News Archive

HanAll Biopharma Co., Ltd. is now accepting applications for the 2023 pharmaceutical industry fellowship program through April 15, 2023.

Intergalactic Therapeutics, a company focused on transforming medicine through non-viral gene therapy, announced today positive preclinical results from its lead program IG-002 addressing all forms of ABCA4-related retinopathies.

Veracyte, Inc. announced that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.

Tandem Diabetes Care, Inc. announced publication of results from the Pediatric Artificial Pancreas Clinical Trial by the New England Journal of Medicine showing an approximate 3-hour per day increase in time in range* in children ages 2-5 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology** compared to those on a standard insulin pump or multiple daily injections.

Invitae, a leading medical genetics company, announced seven studies, including one oral presentation and six posters, to be presented at the 2023 American Clinical Genetics Meeting held in Salt Lake City from March 14-18, 2023.

Akeso Inc. released its 2022 annual report. During the reporting period, the company enjoyed booming business development and made breakthrough progress in drug innovation and development, commercialization and internationalization.

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2022 financial results on Thursday, March 23, 2023, after the close of market.

AptarGroup, Inc. announced that it has updated its Scope 1 and 2 science-based targets, setting an emissions reduction goal consistent with requirements to limit global temperature rise to 1.5° Celsius by year 2030.

Johnson & Johnson will host a conference call for investors at 8:30 a.m. on Tuesday, April 18th to review first-quarter results.

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in endometrial, ovarian, and cervical cancer cell lines.